Position in SYRE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$20,007,580
New position
Shares Held
396,661
first reported quarter
Ownership
0.457%
of shares outstanding
% of Portfolio
0.35%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026SAMLYN CAPITAL, LLC holds $261,566,172 across 7 Biotechnology names. SYRE ranks #7 (7.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
417,205 | $68,221,360 | |
| 2 | RCUS |
Arcus Biosciences, Inc.
|
1,908,412 | $41,221,696 | |
| 3 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
431,115 | $36,179,169 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
371,948 | $36,171,943 | |
| 5 | DYN |
Dyne Therapeutics, Inc.
|
1,922,543 | $34,855,702 | |
| 6 | TERN |
Terns Pharmaceuticals, Inc.
|
472,472 | $24,908,722 | |
| 7 | SYRE |
Spyre Therapeutics, Inc.
This page
|
396,661 | $20,007,580 |
All Filings in SYRE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $20,007,580 | 396,661 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||